APTO-253 LOR-253; LT-253|cas:916151-99-0|西域试剂

APTO-253 LOR-253; LT-253,98.15%

产品编号：Bellancom-16291| CAS NO：916151-99-0| 分子式：C₂₂H₁₄FN₅| 分子量：367.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16291	￥800.00	杭州北京（现货）
Bellancom-16291	￥1200.00	杭州北京（现货）
Bellancom-16291	￥3800.00	杭州北京（现货）
Bellancom-16291	￥5800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

APTO-253 LOR-253; LT-253

产品介绍

APTO-253 (LOR-253) 是一种小分子，可抑制c-Myc表达，稳定 G-四链体 DNA 并诱导急性髓样白血病细胞的细胞周期停滞和凋亡。APTO-253 通过诱导 Kruppel-like factor 4 (KLF4) 抑癌因子介导抗癌活性。APTO-253 具有抗关节炎活性。

生物活性

APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor. APTO-253 has antiarthritic activity.

体外研究

APTO-253 (LOR-253) is an inducer of KLF4. APTO-253 (5 μM) induces KLF4 expression, and enhances apoptosis induced by NSC 119875 in both SKOV3 and OVCAR3 cells. APTO-253 (5 μM) also leads to G1 phase arrest and reduces S and G2/M phase cells in SKOV3 and OVCAR3 cells.
APTO-253 is cytotoxic to Raji and Raji/253R cell lines, with IC₅₀s of 105 ± 2.4 nM and 1387 ± 94 nM, respectively. APTO-253 (0.5 μM) also causes DNA damage in Raji cells. BRCA1/2 deficient cells are hypersensitive to APTO-253. ABCG2 overexpressed HEK-293 cells are resistant to APTO-253 and inhibition of ABCG2 reverses resistance to APTO-253 in Raji/253R.
APTO-253 suppresses the proliferation of acute myeloid leukemia (AML) cell lines and various forms of lymphoma cell lines with IC₅₀s ranging from 57 nM to 1.75 µM. APTO-253 (500 nM) also causes G0/G1 cell cycle arrest, induces apoptosis, and down regulates MYC RNA and protein expression in AML lines. APTO-253 (500 nM) leads to DNA damage response pathways in MV4-11 cells. Futhermore, APTO-253 is a potent stabilizer of Gquadruplex (G4) motifs, and demonstrates the greatest propensity for stabilizing the MYC G4 sequences.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

APTO-253 (LOR-253; 15 mg/kg; IV; twice per day for 2 consecutive days per week for 14 days) has antiarthritic activity in a CIA model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DBA/1J male mice (6 weeks) with collagen induced arthritis (CIA)
Dosage:	15 mg/kg
Administration:	IV; twice per day for 2 consecutive days per week for 14 days
Result:	Demonstrated significant preventive and therapeutic activity on arthritis formation.

体内研究

APTO-253 (LOR-253; 15 mg/kg; IV; twice per day for 2 consecutive days per week for 14 days) has antiarthritic activity in a CIA model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DBA/1J male mice (6 weeks) with collagen induced arthritis (CIA)
Dosage:	15 mg/kg
Administration:	IV; twice per day for 2 consecutive days per week for 14 days
Result:	Demonstrated significant preventive and therapeutic activity on arthritis formation.

性状

Solid

溶解性数据

In Vitro:

DMSO : 60 mg/mL (163.32 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7220 mL	13.6099 mL	27.2198 mL
5 mM	0.5444 mL	2.7220 mL	5.4440 mL
10 mM	0.2722 mL	1.3610 mL	2.7220 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.3 mg/mL (6.26 mM); Suspended solution; Need ultrasonic and warming

此方案可获得 2.3 mg/mL (6.26 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 23.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (5.66 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.66 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明